Enhanced target-specific delivery of docetaxel-loaded nanoparticles using engineered T cell receptors
Authors
McDaid, William JLissin, N.
Pollheimer, E.
Greene, M.
Leach, A.
Smyth, P.
Bossi, G.
Longley, D.
Cole, D. K.
Scott, C. J.
Affiliation
The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK, BT9 7AEIssue Date
2021
Metadata
Show full item recordAbstract
For effective targeted therapy of cancer with chemotherapy-loaded nanoparticles (NPs), antigens that are selective for cancer cells should be targeted to minimise off-tumour toxicity. Human leukocyte antigens (HLAs) are attractive cancer targets as they can present peptides from tumour-selective proteins on the cell surface, which can be recognised by T cells via T cell receptors (TCRs). In this study, docetaxel-loaded polymeric NPs were conjugated to recombinant affinity-enhanced TCRs to target breast cancer cells presenting a tumour-selective peptide-HLA complex. The TCR-conjugated nanoparticles enabled enhanced delivery of docetaxel and induced cell death through tumour-specific peptide-HLA targeting. These in vitro data demonstrate the potential of targeting tumour-restricted peptide-HLA epitopes using high affinity TCR-conjugated nanoparticles, representing a novel treatment strategy to deliver therapeutic drugs specifically to cancer cells.Citation
McDaid WJ, Lissin N, Pollheimer E, Greene M, Leach A, Smyth P, et al. Enhanced target-specific delivery of docetaxel-loaded nanoparticles using engineered T cell receptors. Nanoscale. 2021;13(35):15010–20.Journal
NanoscaleDOI
10.1039/d1nr04001dPubMed ID
34533174Additional Links
https://dx.doi.org/10.1039/d1nr04001dType
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1039/d1nr04001d